All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Join our
How to sequence BCMA-directed therapies in early relapsed/ refractory multiple myeloma
At the ESH 7th Translational Research Conference:
Multiple Myeloma
with Martin Kaiser, Mohamad Mohty, and Rakesh Popat
Saturday, October 5, 2024 | 09:10-10:10 CEST
Register nowThis independent educational activity is funded by GSK. All content is developed independently by the faculty. The funders are allowed no influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The anti–B-cell maturation antigen (BCMA) CAR T-cell bb2121 has been granted both breakthrough therapy designation by the US Food and Drug Administration (FDA) and PRIority MEdicines (PRIME) eligibility by the European Medicines Agency (EMA). Achieving this EMA and FDA status will help to speed up the development process, and is granted to drugs that are highly promising and could change the course of current treatment.
No new data was released with this application, but the latest clinical trial data (phase I CRB-401) treating patients with Relapsed and Refractory Multiple Myeloma (RRMM), is due to be presented at the 59th American Society of Hematology (ASH) 2017 Annual Meeting and Exposition on Monday 11th December at 20:00 GMT – look out for MM Hub coverage next week. Data from the first analysis of the study with 21 patients was revealed in June this year at both the European Hematology Association (EHA) 22nd Annual Congress and also at the American Society of Clinical Oncology (ASCO) Annual Meeting – see MM Hub article.
This will be welcome news for Celgene and Bluebird Bio who are developing bb2121 and plan to extend the clinical trial with the recruitment of 50 new participants. Eligible patients must have undergone 3 prior treatments, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or must be double-refractory, and have ≥50% BCMA expression on the relevant cells.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox